PERRIGO
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The company's test is based on database containing prostate cancer patients, as well as provides decision support for patients and… Read more
PERRIGO (PGO) - Total Liabilities
Latest total liabilities as of June 2024: €18.99 Million EUR
Based on the latest financial reports, PERRIGO (PGO) has total liabilities worth €18.99 Million EUR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PERRIGO - Total Liabilities Trend (2019–2024)
This chart illustrates how PERRIGO's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PERRIGO Competitors by Total Liabilities
The table below lists competitors of PERRIGO ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HUANENG POWER -H-
MU:HUP1
|
Germany | €363.44 Billion |
|
Triad Group PLC
LSE:TRD
|
UK | GBX3.06 Million |
|
bleuacacia ltd Warrants
NASDAQ:BLEUW
|
USA | $11.93 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down PERRIGO's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PERRIGO's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PERRIGO (2019–2024)
The table below shows the annual total liabilities of PERRIGO from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €24.55 Million | +411.50% |
| 2023-06-30 | €4.80 Million | +11.69% |
| 2022-06-30 | €4.30 Million | -52.40% |
| 2019-06-30 | €9.03 Million | -- |